A recent study looked to evaluate the association between infliximab trough levels, response to treatment, and quality of life in a cohort of Brazilian irritable bowel disease (IBD) patients.
Despite the effectiveness of infliximab, an anti-tumor necrosis factor (anti-TNF) antibody in the treatment of ulcerative colitis (UC) and Crohn disease (CD), a substantial number of patients eventually lose disease response.
Infliximab trough levels greater than 2-3 μg/ml have been associated with higher rates of sustained clinical and biochemical remission. A recent study looked to evaluate the association between infliximab trough levels, response to treatment, and quality of life in a cohort of Brazilian irritable bowel disease (IBD) patients.
A transversal study was conducted among 71 patients with CD (55) and UC (16) receiving infliximab maintenance therapy of 5mg/kg. Infliximab trough levels were measured from blood samples collected before drug infusion. Complete remission was evaluated using the Harvey Bradshaw Index and partial Mayo Score for CD and UC, respectively. Mucosal healing (MH) was considered Simple Endoscopic Score ≤2 in CD, or a Mayo Endoscopic Subscore of ≤1 in UC.
Of the 71 patients included in the study, 43 (60.5%) had unsatisfactory infliximab trough levels, 35 (49.3%) had active disease, 4 (5.6%) were in complete remission but not MH, and 32 (45%) were in complete response and MH.
Satisfactory trough level (≥3 μg/mL) were associated with complete response and mucosal healing (P <.001). In addition, quality of life was increased if the trough concentration was higher than ≥3 μg/mL3.
Researchers demonstrated that better quality of life in patients with UC and CD is associated with adequate serum levels of infliximab. Participants in the study displayed improvement in intestinal problems, social function, and systemic manifestations.
According to the study authors, while therapeutic drug monitoring is not routinely conducted within Brazil, it has been shown to improve treatment outcomes and have important economic benefits in patients with IBD. This is because while individualized therapy based on immunopharmacological evidence has similar complete response rates compared to dose intensification strategies.
However, when a physician looks to “blindly” optimize dosing instead of making the decision based off of the patient’s infliximab trough level, the treatment cost is much higher. Although therapeutic drug monitoring can be a useful tool in patients losing disease response, the researchers note that further prospective studies are needed to confirm the results.
Reference
Parra R, Feitosa M, Ribeiro L, Castro L, Rocha J, Feres O. Infliximab trough levels and quality of life in patients with inflammatory bowel disease in maintenance therapy [published online May 8, 2018]. Gastroenterol Res Pract. doi: 10.1155/2018/1952086.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.